Authors: Ines Tagoug, Amélie Sauty De Chalon, Charles Dumontet
DOI: 10.1371/journal.pone.0022641
Abstract Summary
Combining an IGF-1 receptor antibody with an IKK2 inhibitor shows promising results against multiple myeloma cells. The dual therapy enhanced cancer cell death, disrupted mitochondrial function, and blocked NF-κB signaling more effectively than single treatment. This approach could improve outcomes for myeloma patients with high IGF-1 receptor levels.
Why Brain? 🧠
Combining IGF-1 receptor blockade with IKK2 inhibitor enhances myeloma cell death by disrupting survival pathways, offering a potential new dual-target treatment strategy for multiple myeloma patients.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
